Literature DB >> 8323507

Gadolinium-enhanced MRI of soft tissue masses.

K L Harkens1, T E Moore, W T Yuh, M H Kathol, D R Hawes, G Y el-Khoury, K S Berbaum.   

Abstract

The efficacy of gadopentetate dimeglumine (Gd-DTPA) enhanced magnetic resonance (MR) imaging in the diagnosis and differentiation of soft-tissue, neoplastic and non-neoplastic lesion has not been well established. Thirty patients with soft tissue masses (18 neoplastic and 12 non-neoplastic) were studied, using MR imaging with and without administration of Gd-DTPA. Gd-DTPA proved helpful in characterisation of several entities, including differentiation of solid mass from proteinaceous cyst, demonstration of tumour nodules within haemorrhagic or necrotic masses, and delineation of tumour adjacent to oedema. The use of Gd-DTPA may provide additional information for tissue specificity and, in complicated cases, Gd-DTPA may also provide essential information that cannot be obtained using other methods. We recommend the use of contrast enhanced MR as an adjunct to conventional MR imaging in the initial assessment of musculoskeletal soft tissue masses. However, T2-weighted images show better tissue contrast of the lesions, and are equal to contrast enhanced images in delineation of tumour margins. Non-contrast enhanced images are, therefore, probably adequate for the delineation of lesions for surgical planning when a diagnosis has already been made.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8323507     DOI: 10.1111/j.1440-1673.1993.tb00003.x

Source DB:  PubMed          Journal:  Australas Radiol        ISSN: 0004-8461


  2 in total

1.  Comparison of half-dose and full-dose gadolinium MR contrast on the enhancement of bone and soft tissue tumors.

Authors:  Colleen M Costelloe; William A Murphy; Tamara M Haygood; Rajendra Kumar; Kevin W McEnery; R Jason Stafford; Anjali Roy; Roland L Bassett; Robyn K Harrell; John E Madewell
Journal:  Skeletal Radiol       Date:  2010-09-24       Impact factor: 2.199

2.  Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

Authors:  Colleen M Costelloe; Hubert H Chuang; John E Madewell; Naoto T Ueno
Journal:  J Cancer       Date:  2010-06-28       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.